Search
Paritaprevir
go.drugbank.com/drugs/DB09297ApprovedInvestigationalIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) recommend Paritaprevir as a first line … First approved in July 2015, Technivie is indicated in combination with [DB00811] for the treatment of patients with genotype 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated
Categories: Antivirals for treatment of HCV infections, Cytochrome P-450 SubstratesSynonyms: (2R,6S,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo, [1,2-a][1,4]diazacyclopentadecine-14a(5H)-carboxamideAcetohydroxamic acid
go.drugbank.com/drugs/DB00551ApprovedInvestigationalAcetohydroxamic Acid, a synthetic drug derived from hydroxylamine and ethyl acetate, is similar in structure to urea. In the urine, it acts as an antagonist of the bacterial enzyme urease. … It is used, in addition to antibiotics or medical procedures, to treat chronic urea-splitting urinary infections.
Synonyms: N-Hydroxyacetamide, N-AcetylhydroxylamineProducts: QUINOPRON ® INYECTABLE 200 MGEfmoroctocog alfa
go.drugbank.com/drugs/DB11607ApprovedInvestigationalFactor VIII is a blood coagulant factor involved in the intrinsic pathway to form fibrin, or a blood clot. … The B domain of factor VIII is deleted. In animal models of haemophilia, efmoroctocog alfa demonstrated an approximately two-fold longer t½ than commercially available rFVIII products [A31551].
Products: ELOCTATE® 250 UI, ELOCTATE® 500 UIVayarin
go.drugbank.com/drugs/DB09328ApprovedVayarin is a novel therapy for ADHD that appears to be effective in several studies [L1501, L1502, L1503]. … Vayarin is a prescription medical food for the clinical dietary management of certain lipid imbalances blamed to be associated with attention deficit hyperactivity disorder (ADHD) in children.
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme InhibitorsDatopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigationalDatopotamab deruxtecan is an antibody-drug conjugate comprising a Trop-2-directed monoclonal antibody (datopotamab) and a DNA topoisomerase-I inhibitor, DDx. … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Categories: Topoisomerase I Inhibitors, MATE 2 SubstratesMeningococcal polysaccharide vaccine group W-135
go.drugbank.com/drugs/DB13887ApprovedInvestigational*N. meningitidis* is a bacteria that causes endemic and epidemic diseases including meningitis and meningococcemia. … It is subcutaneously administered as an active immunization against the invasive meningococcal disease caused by the serogroup W-135.
Mixtures: MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 5 ADET, MENACTRA 0,5 ML IM ENJEKSİYONLUK ÇÖZELTİ İÇEREN FLAKON, 1 ADETSynonyms: Neisseria meningitidis group W-135 polysaccharide antigen, A, Meningococcal polysaccharide antigen group W-135Rimonabant
go.drugbank.com/drugs/DB06155ApprovedWithdrawnRimonabant is an anorectic anti-obesity drug produced and marketed by Sanofi-Aventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. … Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: ACOMPLIA ® COMPRIMIDOS RECUBIERTOS20 MGCarboprost tromethamine
go.drugbank.com/drugs/DB00429ApprovedInvestigationalA nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
Categories: Prostaglandins F, SyntheticSynonyms: 1,3-dihydroxy-2-(hydroxymethyl)propan-2-aminium (5Z,9α,11β,13E,15S)-9,11,15-trihydroxy-15-methylprosta-5,13-dien-1-oate, 15(S)-15-methyl-PGF2α tromethamine saltMobocertinib
go.drugbank.com/drugs/DB16390ApprovedInvestigationalWithdrawnIt is used specifically in the treatment of non-small cell lung cancer (NSCLC) caused by exon 20 insertion mutations in the _EGFR_ gene,[L38368] which are typically associated with a poorer prognosis ( … [L38319] Mobocertinib, under the brand name Exkivity (Takeda Pharmaceuticals Inc.), was granted accelerated approval by the FDA in September 2021 for the treatment of locally advanced or metastatic
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsImidacloprid
go.drugbank.com/drugs/DB11421ExperimentalVet approvedImidacloprid is a neonicotinoid, which is a class of neuro-active insecticides modeled after nicotine. … Imidacloprid is a patented chemical, Imidacloprid is manufactured by Bayer Cropscience (part of Bayer AG) and sold under trade names Kohinor, Admire, Advantage, Gaucho, Merit, Confidor, Hachikusan, Premise
Mixtures: Advocate Spot-on Solution for Small Dogs, Advocate Spot-on Solution for Large DogsCategories: Compounds used in a research, industrial, or household setting, Heterocyclic Compounds, 1-Ring